10372 studies found for:    NCI
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: recombinant interferon alfa;   Biological: oblimersen sodium;   Other: pharmacological study
2 Completed BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
Conditions: Adult Acute Promyelocytic Leukemia (M3);   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia
Interventions: Drug: BMS-214662;   Other: pharmacological study;   Other: laboratory biomarker analysis
3 Active, not recruiting
Has Results
Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: pazopanib hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
4 Completed Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Recurrent Squamous Cell Carcinoma of the Hypopharynx;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity;   Salivary Gland Squamous Cell Carcinoma;   Stage IV Squamous Cell Carcinoma of the Hypopharynx;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Interventions: Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
5 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweats, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Changes
Interventions: Drug: ibrutinib;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
6 Active, not recruiting Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery
Conditions: Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer
Interventions: Drug: metformin hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis
7 Active, not recruiting Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab;   Drug: fosbretabulin tromethamine
8 Completed Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Promyelocytic Leukemia (M3);   Blastic Phase Chronic Myelogenous Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
Interventions: Drug: vorinostat;   Drug: idarubicin;   Other: laboratory biomarker analysis;   Other: pharmacological study
9 Completed Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: sorafenib tosylate;   Other: pharmacological study
10 Completed EMD 121974 in Treating Patients With Advanced Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cilengitide;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Completed
Has Results
Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
Conditions: Recurrent Thyroid Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Papillary Thyroid Cancer
Interventions: Drug: romidepsin;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
12 Completed Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
Conditions: Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Ovarian Undifferentiated Adenocarcinoma;   Stage III Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: paclitaxel;   Drug: cisplatin;   Drug: topotecan hydrochloride;   Biological: filgrastim
13 Completed Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: bortezomib;   Drug: vorinostat
14 Terminated O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma
Conditions: Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
Interventions: Drug: O6-benzylguanine;   Drug: carmustine;   Other: laboratory biomarker analysis
15 Completed Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
Conditions: Colorectal Cancer;   Familial Adenomatous Polyposis
Interventions: Drug: celecoxib;   Other: placebo;   Drug: eflornithine;   Other: laboratory biomarker analysis;   Other: questionnaire administration
16 Completed Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Bladder Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Regional Transitional Cell Cancer of the Renal Pelvis and Ureter;   Stage III Bladder Cancer;   Stage IV Bladder Cancer;   Transitional Cell Carcinoma of the Bladder
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
17 Unknown  Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer
Condition: Recurrent Prostate Cancer
Interventions: Drug: pazopanib hydrochloride;   Other: active surveillance;   Drug: leuprolide acetate;   Drug: goserelin acetate
18 Recruiting Cisplatin and Radiation Therapy With or Without Triapine in Treating Patients With Previously Untreated Stage IB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Conditions: Cervical Adenocarcinoma;   Cervical Adenosquamous Cell Carcinoma;   Cervical Squamous Cell Carcinoma;   Stage IB Cervical Cancer;   Stage II Vaginal Cancer;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Vaginal Cancer;   Stage IIIA Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma
Interventions: Drug: triapine;   Drug: cisplatin;   Radiation: external beam radiation therapy;   Radiation: brachytherapy;   Other: laboratory biomarker analysis
19 Completed Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Drug: fenretinide
20 Completed Anidulafungin in Treating Immunocompromised Children With Neutropenia
Conditions: Infection;   Neutropenia;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Drug: anidulafungin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years